The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Date and time:
Type:
Richard Bergenstal
University of Minnesota, Minneapolis, USA
Richard M. Bergenstal is an endocrinologist and Executive Director of the International Diabetes Center, HealthPartners Institute, St. Louis Park, MN, USA. He is Clinical Professor in the Department of Medicine at the University of Minnesota, Minneapolis–Saint Paul, MN, USA, and served as President, Science & Medicine of the American Diabetes Association (ADA) in 2010. In 2007, Dr Bergenstal was named the ADA’s Outstanding Physician Clinician of the Year, and in 2010 he was awarded the Banting Medal for Service for outstanding leadership and service to the ADA. He received his MD and endocrine training from the University of Chicago, Chicago, IL, USA, where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983.
Dr Bergenstal’s clinical research has focused on glucose control and diabetes complications and advanced technology, including continuous glucose monitoring (CGM) and automated insulin delivery systems. He has served as a Principal Investigator (PI) of several National Institutes of Health (NIH) trials (DCCT, ACCORD, GRADE) and two technology-focused NIH grants, an insulin dose advisor system and a study of next-generation automated insulin delivery systems, and a Co-PI on a Patient-Centered Outcomes Research Institute grant evaluating CGM versus blood glucose monitoring to guide insulin therapy in the primary care setting.
Dr Bergenstal’s clinical efforts have been directed toward improving systems of care for patients with diabetes by translating new research findings into practice. He studies the effective utilisation of insulin therapy to optimise outcomes in both type 1 and type 2 diabetes. Dr Bergenstal has worked to standardise CGM metrics and the data display in the Ambulatory Glucose Profile Report, which is now being integrated directly into the electronic health record and organised to help guide and personalise diabetes management.
He teaches nationally and internationally on the importance of patient‐centred team care, has been listed in Best Doctors in America since it began in 1992, and has published more than 400 peer-reviewed scientific articles.
Julia Mader
Medical University of Graz, Graz, Austria
Julia Mader is Associate Professor of Medicine at the Division of Endocrinology and Diabetology at the Medical University of Graz, Graz, Austria, and Deputy Head of the Diabetes Outpatient Clinic. She graduated at the Medical University of Graz, where she also trained in Internal Medicine and Endocrinology. Professor Mader was Visiting Professor at the University Hospital of Bern, Bern, Switzerland (2016–2017). She leads the Diabetes Technology Research Unit at the Medical University of Graz.
Professor Mader’s research focuses on diabetes technology with an emphasis on insulin pumps, continuous glucose monitoring, automated insulin delivery systems, decision support systems and technology to monitor diabetic foot syndrome. She has published more than 100 peer-reviewed scientific papers. Professor Mader has received several national and international awards in the field of diabetes technology. She is executive board member of the European Association for the Study of Diabetes (EASD) and chairs the EASD’s Post-Graduate Education Committee. Professor Mader is a management board member of the Austrian Diabetes Society, within which she heads the Diabetes Education Committee, and is a member of the Diabetes Technology Committee. She has authored and co-authored several national guidelines in the field.
Susanne Reger-Tan
University Hospital Essen, Essen, Germany
Susanne Reger-Tan is a Professor of Medicine, currently holding the position of Consultant Diabetologist and Nutritionist at the Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, Essen, Germany, and appointed as Adjunct Professor of Medicine at the Faculty of Medicine, University of Duisburg-Essen, Essen.
Professor Reger-Tan obtained board certifications in Internal Medicine, Endocrinology, and Diabetes in 2010. Additionally, she acquired expertise in Nutritional Medicine, earning her board certification in 2022.
She is interested in digitalised in-hospital diabetes care and throughout her career, Professor Reger-Tan has gained recognition and honours for her exceptional work. In 2022, she was awarded the first prize at the Bytes4Diabetes Award for her project ‘SmartDiabetesCare’. Professor Reger-Tan’s dedication to excellence led to her being acknowledged as a Top National Specialist and a Top Medic for Endocrinology and Lipid Metabolism in the same year by FOCUS magazine.